[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622152":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":12,"responsibleParty":35,"collaborators":38,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":12,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":12,"overallStatus":64,"whyStopped":12,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":12},{"fullName":5,"class":6},"Aristotle University Of Thessaloniki","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"ARM A: Control Arm","NO_INTERVENTION","Wait-and-See approach",null,{"label":14,"type":15,"description":16,"interventionNames":17},"ARM B: Intervention Arm","EXPERIMENTAL","MODUCARE oral capsules., dosage 2 x 3 for 1 month and 1 x 3 for 5 months (total 6 months, as per instructions provided by the manufacturer)",[18],"Dietary Supplement: MODUCARE",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIETARY_SUPPLEMENT","MODUCARE","MODUCARE is classified as a natural dietary supplement, specifically an immune support supplement containing a patented blend of plant sterols and sterolins, primarily beta-sitosterol and beta-sitosterol glucoside, derived from plant sources.",[14],[26],{"name":27,"affiliation":5,"role":28},"Dimitrios Tsolakidis, Dr.Prof.","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"Dimitrios Zouzoulas, MD, MSc, PhD","CONTACT","+306946536065","dzouzoulas@hotmail.gr",{"type":28,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Dimitrios Zouzoulas","Gynecological Oncologist, MSc, PhD, FEBS-BS",[39],{"name":40,"class":41},"INPA S.A.","UNKNOWN","100622152","moducare-versus-wait-and-see-approach-for-histologically-proven-low-grade-cervical-intraepithelial-neoplasia-cin1-100622152",false,"NCT07379905","MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","A Randomized Trial of MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","MODUCIN1","Inclusion Criteria:\n\n* Histologically proven CIN1\n* Any HPV status (negative, positive: high or low risk)\n* Any Pap test result\n* Age 18 - 85 years old\n* ECOG Performance status 0 - 1\n\nExclusion Criteria:\n\n* Pregnancy\n* Low likelihood of patient compliance to treatment protocol and follow-up\n* Previous operation to the cervix\n* Previous pelvic malignancy\n* Pre-existing histologically proven CIN1 \\> 12 months\n* Pre-existing histologically proven CIN2 and\u002For CIN3\n* Hypersensitivity to trial medication",true,"FEMALE","18 Years","85 Years",{"count":55,"type":56},182,"ESTIMATED","INTERVENTIONAL",[59],"NA","MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1).",[62,63],"Low-grade Cervical Intraepithelial Neoplasia","Moducare","NOT_YET_RECRUITING","2026-02-03",{"date":67,"type":68},"2026-02-05","ACTUAL",{"date":70,"type":56},"2026-03-01",{"date":72,"type":56},"2028-03-01",{"name":5,"class":6}]